# Role of Estrogen on Skeletal Outcomes in FHA

> **NCT07010146** · PHASE2 · RECRUITING · sponsor: **University of Virginia** · enrollment: 150 (estimated)

## Conditions studied

- Bone Strength
- Bone Density
- FHA (Functional Hypothalamic Amenorrhea)

## Interventions

- **DRUG:** transdermal 17β-E2 with cyclic progestin
- **DRUG:** oral 17β-E2 with cyclic progestin
- **DRUG:** transdermal EE+LNG

## Key facts

- **NCT ID:** NCT07010146
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010146, "Role of Estrogen on Skeletal Outcomes in FHA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07010146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*